Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × NETWORK × gilteritinib × Clear all

Phase

Phase 3 1 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Docetaxel 7 Radiotherapy 6 Vincristine 5 Etoposide 5 Cyclophosphamide 5 Cisplatin 5 Specimen Handling 4 Paclitaxel 4 Magnetic Resonance Spectroscopy 4 Gemcitabine 4 Doxorubicin 4 Carboplatin 4 Capecitabine 4 pembrolizumab 3 dexamethasone acetate 3 dexamethasone 21-phosphate 3 auricularum 3 Prednisone 3 Oxaliplatin 3 Methotrexate 3 Leucovorin 3 Fluorouracil 3 Dexamethasone 3 Cytarabine 3 Calcium Dobesilate 3 Surgical Procedures, Operative 2 Ramucirumab 2 Radiation 2 Pemetrexed 2 Mitomycin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07425808 2026-02-23

FIT-AML

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡